Systemic inflammation score as a predictor of efficacy and prognosis of immunotherapy in advanced gastric cancer
This study demonstrates that the Systemic Inflammation Score (SIS) serves as an independent predictive biomarker for immunotherapy efficacy and prognosis in patients with advanced gastric cancer, with lower scores correlating with significantly better survival outcomes and treatment responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is not just a single disease growing in one place; it is a complex battle happening inside the body, involving a constant tug-of-war between the tumor and the immune system. The immune system acts as the body's defense force, sending out specialized cells to find and destroy invaders. However, tumors are clever; they can create a local environment that suppresses these defenders or recruits other cells that actually help the cancer grow. In recent years, doctors have developed powerful drugs called immunotherapies that try to wake up the immune system, helping it recognize and attack cancer cells more effectively. This approach has become a standard treatment for advanced stomach cancer, a serious disease that affects millions of people worldwide. Yet, not every patient responds to these drugs in the same way. Some see their tumors shrink dramatically, while others see little change. Because these treatments can be expensive and carry side effects, doctors urgently need a way to predict who will benefit before starting the therapy.
Researchers at the Jiangsu Cancer Hospital in China set out to find a simple clue hidden in the blood that could answer this question. They focused on the body's natural inflammation response. When the body is fighting an infection or dealing with stress, it releases certain types of white blood cells. Some of these cells, like neutrophils and platelets, can sometimes help tumors hide or grow, while others, like lymphocytes, are the primary soldiers that fight cancer. By looking at the balance between these different cells, doctors can get a snapshot of the body's internal state. The researchers combined these cell counts with a measure of the body's nutritional health, specifically the level of a protein called albumin, to create a single score known as the Systemic Inflammation Score. This score was designed to be a straightforward tool, using routine blood tests that are already available in almost every hospital, to see if it could predict how well a patient would do with immunotherapy.
The team studied 105 patients with advanced stomach cancer who were receiving immunotherapy as their first line of treatment between May 2022 and January 2025. Before starting the drugs, the researchers took blood samples from each patient to calculate their Systemic Inflammation Score. They then grouped the patients into three categories based on this score: a low score of zero, a middle score of one, and a high score of two. A score of zero meant the patient had a favorable balance of immune cells and good nutritional levels, while a score of two indicated a less favorable balance with higher inflammation and lower nutritional markers. The researchers then watched these patients closely, tracking how long they went without their cancer getting worse and how often their tumors shrank or stabilized.
The results revealed a clear and striking pattern. Patients with the lowest score, zero, had significantly better outcomes than those with higher scores. On average, the patients with a score of zero went 18 months before their disease progressed. In contrast, those with a score of one lasted about five months, and those with a score of two lasted only three months. The difference was not just about time; it was also about how the tumors responded to the treatment. Among the patients with the best score, nearly 38 percent saw their tumors shrink significantly, and almost all of them, about 97 percent, saw their disease stop growing or shrink. For the group with the highest score, only about 3 percent saw their tumors shrink, and nearly half of them saw their disease get worse despite the treatment. The study showed that this simple blood-based score was a stronger predictor of success than looking at individual cell counts alone.
The researchers concluded that this Systemic Inflammation Score is a reliable way to estimate who will respond well to immunotherapy for advanced stomach cancer. It suggests that patients with a low score, indicating a body that is less inflamed and better nourished, are much more likely to benefit from these powerful drugs. While the study was conducted at a single hospital and involved a specific group of patients, the findings offer a promising, accessible tool for doctors. It points toward a future where treatment plans could be tailored more precisely, ensuring that patients receive the most effective care for their specific biological makeup. The study does not claim to have solved the problem of stomach cancer, but it does provide a clear, practical method for improving how doctors predict the course of the disease and guide their treatment choices.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.